The story of mRNA: From a loose idea to a tool that may help curb Covid

Partofa"freezerfarm,"afootballfield-sizedfacilityforstoringfinishedCovid-19vaccines,underconstructio 3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport




hotspot

author：focus    Page View：7517
Alexis Borisy
Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In
Previous article： Sage's campaign to raise awareness of postpartum depression hits a nerve
Next article： DIEP, the 'gold standard' of breast reconstruction, is under threat